High-grade Glioma - A decade of care in Christchurch.
glioblastoma multiforme
high-grade glioma
radiotherapy
stupp protocol
temozolomide
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
01
05
2019
revised:
12
07
2019
accepted:
29
07
2019
pubmed:
30
8
2019
medline:
11
3
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
High-grade glioma (HGG) is a devastating illness. Our study aimed to investigate outcomes for patients with HGG treated in Christchurch focussing particularly on those diagnosed with glioblastoma mulitforme (GBM); compare GBM survival with international standards; examine factors associated with better prognosis; and assess the involvement of various allied health disciplines. A 10-year retrospective study of patients who were diagnosed and treated for HGG at Christchurch Hospital. Kaplan-Meier method was used to estimate survival. Predefined multivariate analysis was performed to investigate potential prognostic and predictive factors. A total of 363 patients were diagnosed with HGG at a median age of 64 years with a 5-year overall survival of 6.1%. Patients with grade IV tumours had a poorer outcome than grade III patients (P = 0.0002, log-rank test). Eighty-two per cent of patients had a surgical resection or biopsy of the tumour. For those patients with GBM, gross tumour resection followed by radical chemoradiation was associated with better survival compared with needle biopsy (HR = 1.93, P = 0.018); increasing age was negatively associated with survival (HR = 1.02 per additional age year, P = 0.037); however, waiting time between neurosurgery and radiation did not affect survival. Six per cent of patients received formal psychological input. Our survival outcomes were comparable with internationally published series. More research is required to improve survival in HGG, including molecular guided treatment, and better define treatment paradigms, such as for the elderly and frail.
Identifiants
pubmed: 31464076
doi: 10.1111/1754-9485.12944
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
665-673Informations de copyright
© 2019 The Royal Australian and New Zealand College of Radiologists.
Références
New Zealand Cancer Registry. New Cancer Registrations 2016 [Internet]. New Zealand Cancer Registry, Wellington; 2016. Available from: https://www.health.govt.nz/system/files/documents/publications/newcancerregistrations_2016_final.xlsx
Kim SJ-H, Ioannides SJ, Elwood JM. Trends in incidence of primary brain cancer in New Zealand, 1995 to 2010. Aus NZ J Public Health 2015; 39: 148-52.
Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803-20.
Takahashi Y, Nakamura H, Makino K et al. Prognostic value of isocitrate dehydrogenase 1, O-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World J Surg Oncol 2013; 11: 284.
Gramatzki D, Dehler S, Rushing EJ et al. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer 2016; 122: 2206-15.
Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant Temozolomide for Glioblastoma. N Engl J Med [Internet] 2005; 352: 987-96.
Nava F, Tramacere I, Fittipaldo A et al. Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol 2014; 16: 719-27.
Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.
Roa W, Brasher PMA, Bauman G et al. Abbreviated course of radiation therapy in older patients with Glioblastoma Multiforme: a prospective randomized clinical trial. J Clin Oncol [Internet] 2004; 22: 1583-8.
Perry JR, Laperriere N, O’Callaghan CJ et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med [Internet] 2017; 376: 1027-37.
Shaw EG, Seiferheld W, Scott C et al. Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients. Int J Radiat Oncol Biol Phys [Internet] 2003; 57: S135-6.
Li J, Wang M, Won M et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2011; 81: 623-30.
Geurts M, van den Bent MJ. Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush? Neuro Oncol [Internet] 2018; 20: 868-9.
Blumenthal DT, Won M, Mehta MP et al. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro Oncol [Internet] 2018; 18(20): 966-74.
Brzozowska A, Torun A, Mazurkiewicz M. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme. Adv Clin Exp Med 2015; 24: 279-87.
ICRU. Prescribing Recording, and Reporting Photon Beam Therapy (Report 50). ICRU, Oxford, 1993.
ICRU. Prescribing, Recording and Reporting Photon Beam Therapy (Report 62). ICRU, Oxford, 1999.
ICRU. Prescribing Recording and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT) (ICRU Report 83). ICRU, Oxford, 2010.
Padwal JA, Dong X, Hirshman BR, Hoi-Sang U, Carter BS, Chen CC. Superior efficacy of gross total resection in anaplastic astrocytoma patients relative to glioblastoma patients. World Neurosurg [Internet]. 2016; 90: 186-93.
Trifiletti DM, Alonso C, Grover S, Fadul CE, Sheehan JP, Showalter TN. Prognostic implications of extent of resection in glioblastoma: analysis from a large database. World Neurosurg [Internet]. 2017; 103: 330-40.
Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol [Internet] 2004; 6: 227-35.
Kita D, Ciernik IF, Vaccarella S et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology 2009; 33: 17-22.
Morgan ER, Norman A, Laing K, Seal MD. Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study. Curr Oncol [Internet] 2017; 24: e92-8.
Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-26.
Pérez-Larraya JG, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF Phase II trial. J Clin Oncol [Internet] 2011; 29: 3050-5.
Irwin C, Hunn M, Purdie G, Hamilton D. Delay in radiotherapy shortens survival in patients with high grade glioma. J Neurooncol 2007; 85: 339-43.
Blumenthal DT, Won M, Mehta MP et al. Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database. J Clin Oncol [Internet] 2009; 27: 733-9.
Seidlitz A, Siepmann T, Löck S, Juratli T, Baumann M, Krause M. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. Radiat Oncol [Internet] 2015; 10: 172.
Chang SM, Parney IF, Huang W et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA [Internet] 2005; 293: 557-64.
Wick W, Roth P, Hartmann C et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol 2016; 18: 1529-37.
DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. J Clin Oncol [Internet] 2009; 27: 5861-2.
Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-15.
van den Bent MJ, Baumert B, Erridge SC et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet [Internet] 2017; 390: 1645-53.
Jaeckle K, Vogelbaum M, Ballman K et al. (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III Randomized Study of RT vs. RT+TMZ vs. TMZ for Newly Diagnosed 1p/19q-Codeleted Anaplastic Oligodendroglial Tumors. Analysis patients treated original protocol design. Neurology 2016;86(16 Supplement): Abstract PL02.005.
Fekete B, Werlenius K, Örndal C, Rydenhag B. Prognostic factors for glioblastoma patients - a clinical population-based study. Acta Neurol Scand [Internet] 2015; 133: 434-41.
Ford E, Catt S, Chalmers A, Fallowfield L. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro Oncol [Internet] 2012; 14: 392-404.